Its so crazy that last year one of the Quarterlies showed significant one-off costs that caused a big sell off on CR fears.. which is fair enough.
But here we are a year later almost with $68m in the bank, no CR dilution at all (probably never will need a CR unless DMX fails, which is the least of our problems if it does).
Just goes to show us that Nina is incredible. Positive results and the eventual approval of DMX will showcase DXB as a top tier bio. And for the rest of our products, deal makers will line up wanting to fund our other products, knowing that Nina is running the show.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
48.0¢ |
Change
0.010(2.13%) |
Mkt cap ! $288.0M | |||
| Open | High | Low | Value | Volume |
| 47.5¢ | 48.5¢ | 47.0¢ | $525.6K | 1.102M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 6337 | 47.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 49.0¢ | 37500 | 3 |
View Market Depth
| Last trade - 16.10pm 01/08/2025 (20 minute delay) ? |
| DXB (ASX) Chart |